[en] Varicella-zoster virus is a Herpesvirus responsible for three distinct clinical features : chicken pox (varicella), shingles (herpes zoster) and post-zosterian pain (post-herpetic neuralgia). Neurological aspects of these diseases such as complications of chicken pox, viral latency in sensory gan-glia and reactivation as shingles with concurrent and at times subsequent prolonged pain, are the sequels of the invasion of the peripheral nervous system during primary infection. Prevention is achieved by vaccination with a live attenuated virus strain and therapy calls for specific antiviral agents. In many respects, VZV behaves differently from close relatives. In particular, viral latency in the nervous system is quite different from that of other Herpesviri-dae. The recent discovery of the expression and accumulation of some viral regulatory proteins during latency, although VZV latency had always been considered silent, as well as the demonstration that these proteins are immu-nogenic are opening new avenues to investigate the mechanisms of VZV latency and the immune control of VZV reactivation. [fr] Virus de la varicelle et du zona; Système nerveux.
Disciplines :
Immunology & infectious disease
Author, co-author :
Rentier, Bernard ; Université de Liège - ULiège > Département des Sciences de la Vie > Virologie fondamentale et Immunologie
Sadzot-Delvaux, Catherine ; Université de Liège - ULiège > Département des sciences de la vie > Virologie et immunologie
Language :
French
Title :
Le virus de la varicelle et du zona dans le système nerveux : retraite silencieuse ou guérilla permanente ?
Alternative titles :
[en] Varicella-Zoster virus in the nervous system: silent retreat or permanent guerilla?
Kinchington PR. Latency of varicella-zoster virus: a persistently perpexing state. Frontiers in Bioscience 1999 ; 4 : 200-11.
Lungu O, Annunziato PW. Varicella-zoster virus: latency and reactivation. In : Wolff MH, Schünemann S, Schmidt A. eds. Varicella-zoster virus: molecular biology, pathogenesis and clinical aspects, Basel: Karger, 1999 : 61-75.
Cohen JI, Straus SE. Varicella-zoster virus and its replication. In: Fields BN, Knipe DM, Howley P. eds. Fields virology, Philadelphia: Lippincott-Raven publishers, 1996 : 2525-45.
Shieh MT, WuDunn D, Montgomery RI, Esko JD, Spear PG. Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J Cell Biol 1992 ; 116 : 1273-81.
WuDunn D, Spear PG. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate J Virol 1989 ; 63 : 52-8.
Gabel CA, Dubey L, Steinberg SP, Sherman D, Gershon MD, Gershon AA. Varicella-zoster virus glycoprotein oligosaccharides are phosphorylated during posttranslational maturation. J Virol 1989 ; 63 : 4264-76.
Whitley R, Hilty M, Haynes R, and the NIAID Collaborative Antiviral Study Group. Vidarabine therapy of varicella in immunosuppressed patients. J Pediatr 1982 ; 101 : 125-31.
Biron KK, Elion GB. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrobial Agents Chemother 1980 ; 18 : 443-7.
Kavaliotis J, Loukou I, Trachana M, Gombakis N, Tsagaropoulou-Stigga H, Koliouskas D. Outbreak of varicella in a pediatric oncology unit. Med Pediatr Oncol 1998 ; 31 : 166-9.
Grose C. Varicella-zoster virus infections: chickenpox, shingles and varicella vaccine. In: glaser R, Jones JF. eds. Herpesvirus infections, New York: Dekker, 1994 : 117-85.
Bernstein HH, Rothstein EP. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated varicella vaccine. Pediatrics 1993 ; 92 : 833-7.
Gershon MD, Gershon AA. Role of glycoproteins in varicella-zoster virus infection. In: Wolff MH, Schünemann S, Schmidt A. eds. Varicella-zoster virus : molecular biology, pathogenesis and clinical aspects, Basel : Karger, 1999 : 43-60.
Grose C. Glycoproteins encoded by varicella-zoster virus: biosynthesis, phosphorylation, and intracellular trafficking. Annu Rev Microbiol 1990 ; 44 : 59-80.
Gershon AA, Sherman DL, Zhu Z, Gabel CA, Ambron RT, Gershon MD. Intracellular transport of newly synthesized varicella-zoster virus: final envelopment in the trans-Golgi network. J Virol 1994 ; 68 : 6372-90.
Sadzot-Delvaux C, Baudoux L, Defechereux P, Piette J, Rentier B. Overview of the replication cycle of varicella-zoster virus. In: Wolff MH, Schünemann S, Schmidt A. eds Varicella-zoster virus: molecular biology, pathogenesis and clinical aspects. Basel : Karger, 1999 : 21-42.
From the Centers for Disease Control and Prevention. Varicella-related deaths among children-United States, 1997. JAMA 1998 ; 279 : 1773-4.
Locksley RM, Flournoy N, Sullivan KM, Meyers J. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985 ; 152 : 1172-81.
Gershon A. Chickenpox, measles, and mumps. In: Remington J, Klein JO. eds. Infectious diseases of the fetus and newborn. Philadephia : Saunders, 1999 :
Cohen JI, Straus SE. Varicella-zoster virus and its replication. In: Fields BN, Knipe PM, Howley PM. eds. Virology, New York : Lippincott-Raven, 1996 : 2525-45.
Croen KD, Ostrove JM, Dragovic U, Straus SE. Patterns of gene expression and sites of latency in human nerve ganglia are different for varicella-zoster and herpes simplex viruses. Proc Natl Acad Sci USA 1988 ; 85 : 9773-7.
Hyman RW, Ecker JR, Tenser RB. Varicella-zoster virus RNA in human trigeminal ganglia. Lancet 1983 ; 2 : 814-6.
Gilden DH, Rozenman Y, Murray R, Devlin M, Vafai A. Detection of varicella-zoster virus nucleic acid in neurons of normal human thoracic ganglia. Ann Neurol 1987 ; 22 : 377-80.
Meier JL, Holman RP, Croen KD, Smialek JE, Straus SE. Varicella-zoster virus transcription in human trigeminal ganglia. Virology 1993 ; 193 : 193-200.
Lungu O, Annunziato PW, Gershon A, et al. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci USA 1995; 92 : 10980-4.
Cohrs RJ, Barbour MB, Mahalingam R, Wellish M, Gilden DH. Varicella-zoster virus (VZV) transcription during latency in human ganglia: prevalence of VZV gene 21 transcripts in latently infected human ganglia. J Virol 1995 ; 69 : 2674-8.
Cohrs RJ, Barbour M, Gilden DH. Varicella-zoster virus (VZV) transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA. J Virol 1996 ; 70 : 2789-96.
Sadzot-Delvaux C, Merville-Louis MP, Delrée P, et al. An in vivo model of varicella-zoster virus latent infection of dorsal root ganglia. J Neurosci Res 1990 ; 26 : 83-9.
Debrus S, Sadzot-Delvaux C, Nikkels AF, Piette J, Rentier B. Varicella-zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency. J Virol 1995 ; 69 : 3240-5.
Mahalingam R, Wellish M, Cohrs R, et al. Expression of protein encoded by varicella-zoster virus open reading frame 63 in latently infected human ganglionic neurons. Proc Natl Acad Sci USA 1996 ; 93 : 2122-4.
Lungu O, Panagiotidis CA, Annunziato PW, Gershon AA, Silverstein SJ. Aberrant intracellular localization of varicella-zoster virus regulatory proteins during latency. Proc Natl Acad Sci USA 1998 ; 95 : 7080-5.
Straus SE, Ostrove JM, Inchauspé G, et al. Varicella-zoster virus infections, biology, natural history, treatment and prevention. Ann Intern Med 1988 ; 108 : 221-37.
Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965 ; 58 : 9-20.
Feldman S, Hughes WT, Kim HY. Herpes zoster in children with cancer. Am J Dis Child 1973 ; 126 : 178-84.
Veenstra J, Krol A, van Praag R. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection AIDS 1995 ; 9 : 1153-8.
Mahalingam R, Wellish M, Brucklier J, Gilden DH. Persistence of varicella-zoster virus DNA in elderly patients with postherpetic neuralgia. J Neurovirol 1995 ; 1 : 130-3.
Devlin ME, Gilden DH, Mahalingam R, Dueland AN, Cohrs R. Peripheral blood mononuclear cells of the elderly contain varicella-zoster virus DNA. J Infect Dis 1992 ; 165 : 619-22.
Arvin AM, Sharp M, Smith S. et al. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J Immunol 1991 ; 146 : 257-64.
Sadzot-Delvaux C, Kinchington PR, Debrus S, Rentier B, Arvin AM. Recognition of the latency-associated immediate early protein IE63 of varicella-zoster virus by human memory T lymphocytes. J Immunol 1997 ; 159 : 2802-6.
Schmader K. Postherpetic neuralgia in immunocompetent elderly people. Vaccine 1998 ; 16 : 1768-70.
Watson CPN, Morshead C, Van der Kooy D, Evans RJ. Post-herpetic neuralgia: post-mortem analysis of a case. Pain 1988 ; 34 : 129-38.
Watson CPN, Deck JH, Morshead C, Van der Kooy D, Evans RJ. Post-herpetic neuralgia: further post-mortem studies of cases with and without pain Pain 1991 ; 44 : 105-17.
Rentier B. Physiopathologie et pathogenèse des douleurs zostériennes. Méd Mal Infect 1998 ; 28 : 848-50.
Weller TH, Stoddard MB, Intranuclear inclusions bodies in cultures of human tissues inoculated with varicella vesicle fluid. J Immunol 1952 ; 68 : 311-9.
Asano Y. Varicella vaccine: the Japanese experience. J Infect Dis 1996 ; 174 S310-3.
From the Centers for Disease Control. National, state and urban area vaccination coverage levels among children aged 19-35 months - United States, 1997. MMWR 1997 ; 47 : 548-53.
Hardy I, Gershon AA, Steinberg P, LaRussa P The incidence of zoster after immunization with live attenuated varicella vaccine: a study in children with leukemia. N Engl J Med 1991 ; 325 : 1545-50.
Plotkin S, Starr SE, Connore K, Morton D. Zoster in normal children after varicella vaccine. J Infect Dis 1989 ; 159 : 1000-1.
Brunell PA, Taylor-Wiedeman J, Geiser CK, Frierson L, Lydick E. Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox Pediatrics 1986 ; 77 : 53-6.
